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Rates Of Vascular Access Use In Transcatheter Aortic Valve Replacement: A Look
Into The Next Generation
Mir B. Basir, Carlos Velez, Brittany Fuller, Gaetano Paone, Dee Dee Wang,
Mayra Guerrero, Adam Greenbaum, William O’Neill
Henry Ford Hospital, Detroit, MI
BACKGROUND Vascular complications are a major source of morbidity and mortality
associated with transcatheter aortic valve replacement (TAVR). As smaller delivery
systems emerge we sought to identify differences in vascular access use.
METHODS We analyzed all patients who had undergone TAVR in a single center
from March 2012 to May 2014. We identiﬁed all patients who had undergone non-
femoral TAVR. We reviewed the femoral dimensions of all patients using CT imaging
taking into account vessel tortuosity, calciﬁcation, vascular pathology, and two-
dimensional minimal lumen diameter (MLD). We then identiﬁed those patients in
whom a smaller delivery system could have been used if such technology was
available at that time.
RESULTS In total 208 TAVRs were performed,129 cases using femoral arterial access
and 75 cases using non-femoral access. 28 transapical, 27 transcaval, 12 transaortic
and 8 via an antegrade approach using the femoral vein thereafter requiring atrial
septostomy. Of the 75 non-femoral access cases, 63 were completed using commer-
cially available ﬁrst-generation valves and 12 using second-generation valves under
research protocols. MLD required for each delivery system was based on the manu-
facture’s recommendation.
Of the 63 cases performed via a non-femoral route using a ﬁrst generation valve, 31
cases could have been approached via a transfemoral (TF) route using second-gen-
eration delivery systems; and 48 cases could have been approached via a TF route
using third generation delivery systems. Of the 12 cases performed via a non-femoral
route using a second-generation valve, 4 cases could have been approached via a TF
route using a third-generation delivery system.
In total, only 11% patients undergoing TAVR could not accommodate smaller sec-
ond and third generation delivery system. 16 of these 22 patients could not accom-
modate third generation delivery systems due to the small minimal lumen diameter
of the iliofemoral vessels. The other 6 could not accommodate smaller delivery sheath
due to vascular pathology.
CONCLUSION With the use of smaller delivery systems our institution can expect to
perform 89% of TAVRs via a typical retrograde TF approach.
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TriGuard HD Embolic Deﬂection Device For Cerebral Protection During
Transcatheter Aortic Valve Replacement: Results: Of The Deﬂect II Trial
Mariam Samim, Jeroen Hendrikse, Pierfrancesco Agostoni, Bart Van Der Worp,
Ricardo P. Budde, Freek Nijhoff, Faiz Ramjankhan, Pieter A. Doevendans,
Pieter R. Stella
University Medical Center Utrecht, Utrecht, Netherlands
BACKGROUND Periprocedural stroke and concerns regarding subclinical cerebral
embolic events in transcatheter aortic valve replacement (TAVR) have prompted
investigation towards preventive measures. Purpose of this study is to evaluate the
safety and performance of the second generation embolic deﬂection device Tri-
GuardHD (Keystone Heart, Herzliya, Israel) in patients undergoing TAVR.
METHODS This prospective, single-arm, feasibility study included 15 patients with
severe symptomatic aortic stenosis scheduled for TAVR. Cerebral diffusion weighted
magnetic resonance imaging (DWI) was planned in all patients one day before and atday 4 (2) after the procedure. Major adverse cerebral and cardiac events (MACCEs)
and neurological status, including NIH Stroke Scale (NIHSS) and the modiﬁed Rankin
Scale (mRS) scores, were recorded for all patients. Primary endpoints of this study
were I) device performance success deﬁned as complete coverage of the three major
cerebral arteries throughout the whole TAVR procedure and II) MACCE occurrence.
Secondary endpoints included the number and volume of new cerebral lesions on
DWI.
RESULTS Fourteen patients underwent transfemoral TAVR and one patient a trans-
apical procedure. An Edwards SAPIEN prosthesis was implanted in 9 (60%) and a
Medtronic CoreValve in 6 (40%) patients. Predeﬁned performance success of the
TriGuardHD device was achieved in 10 (67 %) patients. MACCE occurred in none of
the patients. NIH Stroke Scale scores were 0 in all patients on admission and
remained unchanged during hospital stay. Modiﬁed Rankin Scale scores ranged from
0 to 3 (average 2.1) on admission and remained unchanged during hospitalization.
Pre- and post-procedural DWI was performed in 8 patients with device performance
success and showed 4.0 [1.0-8.8] new lesions per patient with 12.1 [7.7-20.8] mL lesion
volume and 64.6 [11.9-147.8] mL total ischemic volume.
CONCLUSION The use of the TriGuardHD for cerebral protection during TAVR is
safe. Performance success was achieved in 67% of all cases. TriGuardHD shows
important reduction in volume of post-procedural cerebral ischemic lesions
compared to regular (unprotected) TAVR cases.
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Contemporary Outcomes of Patients Undergoing Balloon Aortic Valvuloplasty
who were Initially Excluded from Transcatheter Aortic Valve Replacement
Sarkis Kiramijyan, Ricardo O. Escarcega, Rebecca Torguson, Joelle S. Salmon,
Sandeep Kumar, Marcus Weaver, Mia A. Spad, Kassaye T. Sesaba, Edward Koifman,
Marco A. Magalhaes, Nevin C. Baker, Michael J. Lipinski, Smita I. Negi, Ota Hideaki,
Won Yu Kang, Romain Didier, Zachary D. Jerusalem, Petros Okubagzi, Itsik Ben-Dor,
William O. Suddath, Lowell F. Satler, Augusto D. Pichard, Ron Waksman
MedStar Washington Hospital Center, Washington, DC
BACKGROUND The utilization of balloon aortic valvuloplasty (BAV) as a bridge
therapy to transcatheter aortic valve replacement (TAVR) in addition to its well
established use in palliative therapy for patients not eligible for TAVR has become
widespread in recent years. We sought to understand the contemporary outcomes of
patients undergoing BAV who were initially excluded from TAVR.
METHODS We retrospectively analyzed all patients referred to our center from
January 2010 through July 2013 who subsequently underwent BAV. All baseline,
procedural and post-procedural characteristics were evaluated. Longitudinal follow-
up for subsequent clinic visits and further eligibility for TAVR were performed. The
total cohort was divided into two groups: patients who underwent only one BAV vs.
more-than one BAV.
RESULTS A total of N¼366 patients who were initially excluded from TAVR and
assigned to undergo BAV were included in this analysis with n¼326 having only 1 BAV
and n¼40 with >1 BAV. There were no signiﬁcant differences in baseline character-
istics among the two groups with a mean age of 82+/-8 years, 49% male, and STS score
of 8.8+/-5.5. Outcomes following the pre-stated BAV groupings are demonstrated in
the ﬁgure. 1% of the patients (n¼4) underwent >2 BAV procedures with 1 of these
patients subsequently undergoing TAVR. For patients who underwent an initial BAV,
the mean time to a repeat BAV was 20+/-84 days. The mean time to TAVR was 168+/-
188 days for the 1 BAV group vs. 270+/-161 days for the >1 BAV group.
CONCLUSION Among patients initially excluded from TAVR, BAV remains an
important tool in the therapy of patients with severe symptomatic aortic stenosis for
the purposes of either bridging to TAVR or for palliative management. However,
repeat BAV is associated with a high mortality rate, and TAVR should be considered as
an initial therapy in this subgroup.
